Insud Pharma
Vasu Morla has extensive experience in quality assurance within the pharmaceutical industry, currently serving as the Assistant General Manager of Global CQA at Insud Pharma since July 2021, after progressing from Senior Manager in the same department. Prior to this role, Vasu Morla was a Manager in Global CQA at SUN PHARMA from May 2018 to June 2021. Vasu Morla began the career at Apotex Inc. in February 2007 as a Group Leader and previously held an Auditor position at QPS Bioserve Pvt Ltd. from December 2005 to January 2007. Vasu Morla holds a Post Graduate Program in Quality Assurance in Clinical Research from Cliniminds, New Delhi, completed in 2009, and a Post Graduate Diploma in Clinical Research from Catalyst Clinical Services, Delhi, completed in 2008.
This person is not in any offices
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.